TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
AVKARE
Drug class
Pyrimidine Synthesis Inhibitors
Pyrimidine synthesis inhibitors are an established pharmacologic class of immunomodulatory agents that block de novo pyrimidine nucleotide production. Read more about Pyrimidine Synthesis Inhibitors
24 drugs in this class 20 manufacturers
Drugs in Pyrimidine Synthesis Inhibitors
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
AVPAK
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
A-S MEDICATION
TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
DR.REDDY'S LAB
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
CHARTWELL RX LL
TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
ALEMBIC PHARMAC
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
BRYANT RANCH PR
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
AUROBINDO PHARM
TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
AUROBINDO PHARM
Filter & compare in the drug finder →
Opens the drug finder with Pyrimidine Synthesis Inhibitors preselected. Add indication or manufacturer filters there.
Pyrimidine synthesis inhibitors are an established pharmacologic class of immunomodulatory agents that block de novo pyrimidine nucleotide production.
They exert their therapeutic effect primarily by inhibiting dihydroorotate dehydrogenase, a key mitochondrial enzyme essential for generating the pyrimidines required for DNA and RNA synthesis in rapidly proliferating cells.
By arresting lymphocytes in the G1 phase and reducing active T- and B-cell proliferation, these agents suppress targeted immune-mediated inflammatory cascades.
In clinical practice, members of this class—most notably leflunomide and teriflunomide—are primarily indicated for the management of autoimmune disorders, specifically active rheumatoid arthritis and relapsing forms of multiple sclerosis.
-
fda.gov
Pyrimidine synthesis inhibitors are an established pharmacologic class of immunomodulatory agents that block de novo pyrimidine nucleotide production
-
nih.gov
Pyrimidine synthesis inhibitors are an established pharmacologic class of immunomodulatory agents that block de novo pyrimidine nucleotide production They exert their therapeutic effect primarily by inhibiting dihydroorotate dehydrogenase, a key mitochondrial enzyme essential for generating the pyrimidines required for DNA and RNA synthesis in rapidly proliferating cells
-
fda.gov
They exert their therapeutic effect primarily by inhibiting dihydroorotate dehydrogenase, a key mitochondrial enzyme essential for generating the pyrimidines required for DNA and RNA synthesis in rapidly proliferating cells By arresting lymphocytes in the G1 phase and reducing active T- and B-cell proliferation, these agents suppress targeted immune-mediated inflammatory cascades
-
rxce.com
By arresting lymphocytes in the G1 phase and reducing active T- and B-cell proliferation, these agents suppress targeted immune-mediated inflammatory cascades
-
fda.gov
In clinical practice, members of this class—most notably leflunomide and teriflunomide—are primarily indicated for the management of autoimmune disorders, specifically active rheumatoid arthritis and relapsing forms of multiple sclerosis
-
fda.gov
In clinical practice, members of this class—most notably leflunomide and teriflunomide—are primarily indicated for the management of autoimmune disorders, specifically active rheumatoid arthritis and relapsing forms of multiple sclerosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.